Does Rallies show 13F holders for AVIR?

Yes. Rallies tracks hedge fund and 13F ownership data for AVIR, including fund names, share counts, latest tracked quarter, and position changes when available.

Is AVIR research on Rallies investment advice?

No. Rallies provides research, data, and educational context for AVIR. It does not provide personalized investment advice.

AVIR (Atea Pharmaceuticals, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Atea Pharmaceuticals, Inc. Common Stock (AVIR) is a publicly traded Healthcare sector company. As of May 21, 2026, AVIR trades at $4.43 with a market cap of $331.31M and a P/E ratio of -2.15. AVIR moved +0.96% today. Year to date, AVIR is +22.87%; over the trailing twelve months it is +44.48%. Its 52-week range spans $2.46 to $6.45. Analyst consensus is buy with an average price target of $8.00. Rallies surfaces AVIR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns AVIR stock?

Hedge funds tracked by Rallies that own AVIR include Berkshire Asset and Pinebridge Investments. The latest tracked quarter is Sep 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Atea Pharmaceuticals, Inc. Common Stock.

AVIR Key Metrics

Key financial metrics for AVIR
Metric	Value
Price	$4.43
Market Cap	$331.31M
P/E Ratio	-2.15
EPS	$-1.94
Dividend Yield	0.00%
52-Week High	$6.45
52-Week Low	$2.46
Volume	6
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-158.35M
Gross Margin	0.00%

Top Hedge Funds Holding AVIR

Berkshire Asset holds 65.00K shares of AVIR, changed +0.00% as of Sep 30, 2024.
Pinebridge Investments holds 38.34K shares of AVIR, changed +0.00% as of Sep 30, 2023.

Latest AVIR News

Atea to Showcase Bemnifosbuvir-Ruzasvir and AT-587 Data at EASL Congress — May 13, 2026
Atea Pharmaceuticals Plans Mid-2026 C-BEYOND Readout, C-FORWARD Enrollment Completion and HEV Phase 1 Start — May 12, 2026
Atea’s AT-587 Demonstrates 30-150× HEV Inhibition, Progressing to Phase 1 — Feb 24, 2026

Recent AVIR Insider Trades

BERGER FRANKLIN M bought 10.00K (~$33.61K) on Jan 16, 2025.
BERGER FRANKLIN M sold 10.00K (~$33.61K) on Jan 16, 2025.
BERGER FRANKLIN M bought 15.00K (~$47.88K) on Jan 15, 2025.

AVIR Analyst Consensus

3 analysts cover AVIR: 0 strong buy, 2 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $8.00.

Common questions about AVIR

Who owns AVIR stock?: Hedge funds tracked by Rallies that own AVIR include Berkshire Asset and Pinebridge Investments. The latest tracked quarter is Sep 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Atea Pharmaceuticals, Inc. Common Stock.
Does Rallies show 13F holders for AVIR?: Yes. Rallies tracks hedge fund and 13F ownership data for AVIR, including fund names, share counts, latest tracked quarter, and position changes when available.
Is AVIR research on Rallies investment advice?: No. Rallies provides research, data, and educational context for AVIR. It does not provide personalized investment advice.